Sanofi SA plans to generate more than €10 billion in sales from the launch of new pharmaceuticals by 2030 as part of a restructuring outlined by Paul Hudson, the chief executive in 2023. Updating the plans on 1 February, Mr Hudson said that Sanofi is on track to complete development of 12 new medicines, of which two are indicated for multiple sclerosis and one for atopic dermatitis. At the same time, the company is moving ahead with plans to spin out its consumer healthcare business in order to focus exclusively on biopharmaceutical and vaccine development.
